The plaintiffs allege among other things that AstraZeneca engaged in monopoly practices that forced them to pay higher prices for Toprol. They say the company withheld information from federal patent officials in order to fraudulently obtain Toprol-related patents, then restricted generic competition by filing sham patent-infringement lawsuits against rival manufacturers.
No comments:
Post a Comment